Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Regeneron Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 773.09 · gapped above the open, then crossed back over prior close. High/low 791.89 at 8:00 am ET, 773.09 at 4:00 pm ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of REGN revenue | Skew |
|---|---|---|---|
| NVSNovartis | 0.48% | 1.90% | 4.0× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the years ended December 31, 2025 and 2024, our product sales to two distributor customers accounted on a combined basis for 77% and 74% of our total gross product revenue, respectively.”
$11.0B relationship
basisREGN fy2025 · closed 2025-12 $14.3B
FILING10-K0000872589-26-000008cik 0000872589
“Royalties on sales of Novartis' Ilaris ® (canakinumab)”
$273M relationship4.0× more of REGN’s book than NVS’s
basisREGN fy2025 · closed 2025-12 $14.3BNVS fy2025 · closed 2025-12 $56.7B
FILING10-K0000872589-26-000008
“In connection with our license agreement with Kiniksa Pharmaceuticals, Ltd., we are entitled to receive 50% of Kiniksa's profits from sales of ARCALYST”
$229M relationship
basisREGN fy2025 · closed 2025-12 $14.3B
FILING10-K0000872589-26-000008
“In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in a planned clinical trial of patients with unresectable or metastatic RAS-mutant non-small cell lung cancer.”
FILING10-K0001790340-26-000042cik 0001790340disclosed by IMRX
“Regeneron is the sole manufacturer of ARCALYST drug substance and will remain so until we complete the technology transfer of the manufacturing process for ARCALYST drug substance to Samsung.”
FILING10-K0001104659-26-019168cik 0001730430disclosed by KNSA
“All of our revenue to date has been generated from the Regeneron Agreement, which is a collaboration and license agreement.”
FILING10-K0001720580-26-000008cik 0001720580disclosed by ACET
“Partially offset by: • recognition of $185.0 million of revenue under our collaboration with Regeneron during the year ended December 31, 2024, as we modified the collaboration agreement in June 2024 and provided Regeneron with an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy; • recognition of $65.0 million of milestone revenue under our collaboration with Roche during the year ended December 31, 2024 associated with the dosing of the first patient in the KARDIA-3 Phase 2 clinical trial of zilebesiran; and • revenue recognized under our license agreement with Novartis associated with the achievement of a specified Leqvio commercialization milestone during the year ended December 31, 2024.”
FILING10-K0001628280-26-007497cik 0001178670disclosed by ALNY
“Pursuant to the Regeneron Agreement, Regeneron made an upfront payment of $30.0 million to us.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“License fee revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million.”
FILING10-K0002007919-26-000006cik 0002007919disclosed by INBX
“The increase in collaboration revenue during the year ended December 31, 2025 is due to a $23.7 million increase, primarily in cost reimbursements related to our collaboration with Regeneron Pharmaceuticals, Inc. ("Regeneron")”
FILING10-K0001193125-26-076550cik 0001652130disclosed by NTLA
“Our gamma delta T cell-based product candidates and substantially all of our intellectual property have been developed by us, with certain antigen binding domains derived from our collaboration with Regeneron.”
FILING10-K0001720580-26-000008cik 0001720580disclosed by ACET
“Under the collaboration agreement, Regeneron supplies the product and charges the Company a transfer price from the low 20 % range up to 40 % on net sales, which is recognized as cost of sales in the Company's Statement of Operations.”
FILING10-K0000950170-25-023312cik 0001515673disclosed by RARE
“We have also entered into a clinical collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted thereunder.”
FILING10-K0001628280-26-045886cik 0001737953disclosed by REPL
“Bayer records net product sales of EYLEA 8 mg and EYLEA outside the United States.”
FILING10-K0001804220-25-000011cik 0000872589
“Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales based on a pre-specified formula.”
FILING10-K0001804220-25-000011cik 0000872589
“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.”
FILING10-K0001804220-25-000011cik 0000872589
“In May 2026, we entered into a license and collaboration agreement with Regeneron Pharmaceuticals, Inc.”
FILINGS-1/A0001193125-26-262880cik 0001657677disclosed by PBLS
“We lease laboratory and office facilities for our corporate headquarters in Tarrytown, New York (the "Facility") under the Third Amended and Restated Lease and Remedies Agreement (the "Lease") with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing & Capital, LLC ("BAL"), as lessor, and the Third Amended and Restated Participation Agreement (the "Participation Agreement") with Bank of America, N.A., as administrative agent, and a syndicate of lenders (collectively with BAL, the "Participants"), as rent assignees.”
FILING10-K0001804220-25-000011cik 0000872589
“We lease laboratory and office facilities for our corporate headquarters in Tarrytown, New York (the "Facility") under the Third Amended and Restated Lease and Remedies Agreement (the "Lease") with BA Leasing BSC, LLC, an affiliate of Banc of America Leasing & Capital, LLC ("BAL"), as lessor, and the Third Amended and Restated Participation Agreement (the "Participation Agreement") with Bank of America, N.A., as administrative agent, and a syndicate of lenders (collectively with BAL, the "Participants"), as rent assignees.”
FILING10-K0001804220-25-000011cik 0000872589
“Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.”
FILING10-K0001804220-25-000011cik 0000872589
“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.”
FILING10-K0001804220-25-000011cik 0000872589
“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.”
FILING10-K0001804220-25-000011cik 0000872589
“As a result, we rely in part on Sanofi's sales and marketing organization for Dupixent.”
FILING10-K0001804220-25-000011cik 0000872589
“Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.”
FILING10-K0001804220-25-000011cik 0000872589
Watchlist prices, news filtered to it, and its next report on your desk.
Regeneron Pharmaceuticals, Inc. has 15 disclosed suppliers and 13 disclosed customers. Each one is named in an SEC filing, either Regeneron Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
REGN (Regeneron Pharmaceuticals, Inc.) has 15 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ACET −15.62%, in the health bundle.